Dysregulation of peripheral expression of the YWHA genes during conversion to psychosis.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
17 06 2020
Historique:
received: 13 12 2019
accepted: 04 05 2020
entrez: 20 6 2020
pubmed: 20 6 2020
medline: 15 12 2020
Statut: epublish

Résumé

The seven human 14-3-3 proteins are encoded by the YWHA-gene family. They are expressed in the brain where they play multiple roles including the modulation of synaptic plasticity and neuronal development. Previous studies have provided arguments for their involvement in schizophrenia, but their role during disease onset is unknown. We explored the peripheral-blood expression level of the seven YWHA genes in 92 young individuals at ultra-high risk for psychosis (UHR). During the study, 36 participants converted to psychosis (converters) while 56 did not (non-converters). YWHA genes expression was evaluated at baseline and after a mean follow-up of 10.3 months using multiplex quantitative PCR. Compared with non-converters, the converters had a significantly higher baseline expression levels for 5 YWHA family genes, and significantly different longitudinal changes in the expression of YWHAE, YWHAG, YWHAH, YWHAS and YWAHZ. A principal-component analysis also indicated that the YWHA expression was significantly different between converters and non-converters suggesting a dysregulation of the YWHA co-expression network. Although these results were obtained from peripheral blood which indirectly reflects brain chemistry, they indicate that this gene family may play a role in psychosis onset, opening the way to the identification of prognostic biomarkers or new drug targets.

Identifiants

pubmed: 32555255
doi: 10.1038/s41598-020-66901-1
pii: 10.1038/s41598-020-66901-1
pmc: PMC7299951
doi:

Substances chimiques

14-3-3 Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

9863

Investigateurs

Isabelle Amado (I)
Julie Bourgin (J)
Claire Daban Huard (C)
Célia Jantac Mam-Lam-Fook (C)
Marion Plaze (M)
Fabrice Rivollier (F)

Références

McGorry, P. D. Early clinical phenotypes, clinical staging, and strategic biomarker research: building blocks for personalized psychiatry. Biol. Psychiatry 74, 394–395 (2013).
pubmed: 23968984 doi: 10.1016/j.biopsych.2013.07.004
Fusar-Poli, P. et al. The psychosis high-risk state: a comprehensive state-of-the-art review. JAMA Psychiatry 70, 107–120 (2013).
pubmed: 23165428 pmcid: 4356506 doi: 10.1001/jamapsychiatry.2013.269
Chaumette, B. et al. Longitudinal Analyses of Blood Transcriptome During Conversion to Psychosis. Schizophr. Bull. 1, 45(1), 247–255 (2019).
Kebir, O. et al. Methylomic changes during conversion to psychosis. Mol. Psychiatry 22, 512–518 (2017).
pubmed: 27113994 doi: 10.1038/mp.2016.53
Berg, D., Holzmann, C. & Riess, O. 14-3-3 proteins in the nervous system. Nat. Rev. Neurosci. 4, 752–762 (2003).
pubmed: 12951567 doi: 10.1038/nrn1197
Foote, M. & Zhou, Y. 14-3-3 proteins in neurological disorders. Int. J. Biochem. Mol. Biol. 3, 152–164 (2012).
pubmed: 22773956 pmcid: 3388734
Aitken, A. 14-3-3 proteins: a historic overview. Semin. Cancer Biol. 16, 162–172 (2006).
pubmed: 16678438 doi: 10.1016/j.semcancer.2006.03.005
Moore, B. W. Specific acidic proteins of the nervous system. Physiol. Biochem. Asp. Nerv. Integr. 343–359 (1967).
Jones, D. H., Ley, S. & Aitken, A. Isoforms of 14-3-3 protein can form homo- and heterodimers in vivo and in vitro: implications for function as adapter proteins. FEBS Lett. 368, 55–58 (1995).
pubmed: 7615088 doi: 10.1016/0014-5793(95)00598-4
Muslin, A. J., Tanner, J. W., Allen, P. M. & Shaw, A. S. Interaction of 14-3-3 with signaling proteins is mediated by the recognition of phosphoserine. Cell 84, 889–897 (1996).
pubmed: 8601312 doi: 10.1016/S0092-8674(00)81067-3
Yaffe, M. B. et al. The structural basis for 14-3-3:phosphopeptide binding specificity. Cell 91, 961–971 (1997).
pubmed: 9428519 doi: 10.1016/S0092-8674(00)80487-0
Cornell, B. & Toyo-oka, K. 14-3-3 Proteins in Brain Development: Neurogenesis, Neuronal Migration and Neuromorphogenesis. Front. Mol. Neurosci. 10 (2017).
Li, Y., Wu, Y. & Zhou, Y. Modulation of inactivation properties of CaV2. 2 channels by 14-3-3 proteins. Neuron 51, 755–771 (2006).
pubmed: 16982421 doi: 10.1016/j.neuron.2006.08.014
Simsek-Duran, F., Linden, D. J. & Lonart, G. Adapter protein 14-3-3 is required for a presynaptic form of LTP in the cerebellum. Nat. Neurosci. 7, 1296–1298 (2004).
pubmed: 15543142 doi: 10.1038/nn1348
Toyo-oka, K. et al. 14-3-3epsilon is important for neuronal migration by binding to NUDEL: a molecular explanation for Miller-Dieker syndrome. Nat. Genet. 34, 274–285 (2003).
pubmed: 12796778 doi: 10.1038/ng1169
Ichimura, T., Isobe, T., Okuyama, T., Yamauchi, T. & Fujisawa, H. Brain 14-3-3 protein is an activator protein that activates tryptophan 5-monooxygenase and tyrosine 3-monooxygenase in the presence of Ca2+,calmodulin-dependent protein kinase II. FEBS Lett. 219, 79–82 (1987).
pubmed: 2885229 doi: 10.1016/0014-5793(87)81194-8
Alexandre, C. et al. Paradoxical Improvement of Schizophrenic Symptoms by a Dopaminergic Agonist: An Example of Personalized Psychiatry in a Copy Number Variation–Carrying Patient. Biol. Psychiatry 80, e21–e23 (2016).
pubmed: 26602590 doi: 10.1016/j.biopsych.2015.09.017
Ikeda, M. et al. Identification of YWHAE, a gene encoding 14-3-3epsilon, as a possible susceptibility gene for schizophrenia. Hum. Mol. Genet. 17, 3212–3222 (2008).
pubmed: 18658164 doi: 10.1093/hmg/ddn217
Jia, Y. et al. An association study between polymorphisms in three genes of 14-3-3 (tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein) family and paranoid schizophrenia in northern Chinese population. Eur. Psychiatry J. Assoc. Eur. Psychiatr. 19, 377–379 (2004).
doi: 10.1016/j.eurpsy.2004.07.006
Pulver, A. E. et al. Sequential strategy to identify a susceptibility gene for schizophrenia: report of potential linkage on chromosome 22q12-q13.1: Part 1. Am. J. Med. Genet. 54, 36–43 (1994).
pubmed: 8178837 doi: 10.1002/ajmg.1320540108
Toyooka, K. et al. 14-3-3 protein eta chain gene (YWHAH) polymorphism and its genetic association with schizophrenia. Am. J. Med. Genet. 88, 164–167 (1999).
pubmed: 10206237 doi: 10.1002/(SICI)1096-8628(19990416)88:2<164::AID-AJMG13>3.0.CO;2-3
Wong, A. H. C. et al. Identification of candidate genes for psychosis in rat models, and possible association between schizophrenia and the 14-3-3eta gene. Mol. Psychiatry 8, 156–166 (2003).
pubmed: 12610648 doi: 10.1038/sj.mp.4001237
Wong, A. H. C. et al. Genetic and post-mortem mRNA analysis of the 14-3-3 genes that encode phosphoserine/threonine-binding regulatory proteins in schizophrenia and bipolar disorder. Schizophr. Res. 78, 137–146 (2005).
pubmed: 16054338 doi: 10.1016/j.schres.2005.06.009
Cai, L. et al. Implications of Newly Identified Brain eQTL Genes and Their Interactors in Schizophrenia. Mol. Ther. Nucleic Acids 12, 433–442 (2018).
pubmed: 30195780 pmcid: 6041437 doi: 10.1016/j.omtn.2018.05.026
English, J. A., Pennington, K., Dunn, M. J. & Cotter, D. R. The neuroproteomics of schizophrenia. Biol. Psychiatry 69, 163–172 (2011).
pubmed: 20887976 doi: 10.1016/j.biopsych.2010.06.031
Saia-Cereda, V. M., Cassoli, J. S., Martins-de-Souza, D. & Nascimento, J. M. Psychiatric disorders biochemical pathways unraveled by human brain proteomics. Eur. Arch. Psychiatry Clin. Neurosci. 267, 3–17 (2017).
pubmed: 27377417 doi: 10.1007/s00406-016-0709-2
Qing, Y. et al. Dysregulated 14-3-3 Family in Peripheral Blood Leukocytes of Patients with Schizophrenia. Sci. Rep. 6, 23791 (2016).
pubmed: 27030512 pmcid: 4814835 doi: 10.1038/srep23791
English, J. A., Dicker, P., Föcking, M., Dunn, M. J. & Cotter, D. R. 2-D DIGE analysis implicates cytoskeletal abnormalities in psychiatric disease. Proteomics 9, 3368–3382 (2009).
doi: 10.1002/pmic.200900015 pubmed: 19562803
Nesvaderani, M., Matsumoto, I. & Sivagnanasundaram, S. Anterior hippocampus in schizophrenia pathogenesis: molecular evidence from a proteome study. Aust. N. Z. J. Psychiatry 43, 310–322 (2009).
pubmed: 19296286 doi: 10.1080/00048670902721103
Pennington, K., Dicker, P., Dunn, M. J. & Cotter, D. R. Proteomic analysis reveals protein changes within layer 2 of the insular cortex in schizophrenia. Proteomics 8, 5097–5107 (2008).
pubmed: 19003868 doi: 10.1002/pmic.200800415
Rivero, G. et al. Up-regulated 14-3-3β and 14-3-3ζ proteins in prefrontal cortex of subjects with schizophrenia: effect of psychotropic treatment. Schizophr. Res. 161, 446–451 (2015).
pubmed: 25549848 doi: 10.1016/j.schres.2014.12.014
Cornell, B., Wachi, T., Zhukarev, V. & Toyo-Oka, K. Overexpression of the 14-3-3gamma protein in embryonic mice results in neuronal migration delay in the developing cerebral cortex. Neurosci. Lett. 628, 40–46 (2016).
pubmed: 27288018 doi: 10.1016/j.neulet.2016.06.009
Cornell, B., Wachi, T., Zhukarev, V. & Toyo-Oka, K. Regulation of neuronal morphogenesis by 14-3-3epsilon (Ywhae) via the microtubule binding protein, doublecortin. Hum. Mol. Genet. 25, 4405–4418 (2016).
pubmed: 28173130 pmcid: 6078596 doi: 10.1093/hmg/ddw270
Kim, H. S., Ullevig, S. L., Nguyen, H. N., Vanegas, D. & Asmis, R. Redox regulation of 14-3-3ζ controls monocyte migration. Arterioscler. Thromb. Vasc. Biol. 34, 1514–1521 (2014).
pubmed: 24812321 pmcid: 4065841 doi: 10.1161/ATVBAHA.114.303746
Kim, Y. S. et al. Protein kinase Cdelta is associated with 14-3-3 phosphorylation in seizure-induced neuronal death. Epilepsy Res. 92, 30–40 (2010).
pubmed: 20813501 doi: 10.1016/j.eplepsyres.2010.08.004
Lee, D.-H. et al. Role of glial 14-3-3 gamma protein in autoimmune demyelination. J. Neuroinflammation 12, 187 (2015).
pubmed: 26438180 pmcid: 4595275 doi: 10.1186/s12974-015-0381-x
Pennington, K. L., Chan, T. Y., Torres, M. P. & Andersen, J. L. The dynamic and stress-adaptive signaling hub of 14-3-3: emerging mechanisms of regulation and context-dependent protein–protein interactions. Oncogene 37, 5587–5604 (2018).
pubmed: 29915393 pmcid: 6193947 doi: 10.1038/s41388-018-0348-3
Wang, Y. et al. Epigenetic changes of TIMP-3, GSTP-1 and 14-3-3 sigma genes as indication of status of chronic inflammation and cancer. Int. J. Biol. Markers 29, e208–214 (2014).
pubmed: 25041782 doi: 10.5301/jbm.5000104
Chan, M. K. et al. Development of a blood-based molecular biomarker test for identification of schizophrenia before disease onset. Transl. Psychiatry 5, e601 (2015).
pubmed: 26171982 pmcid: 5068725 doi: 10.1038/tp.2015.91
Fournier, M. et al. Impaired metabolic reactivity to oxidative stress in early psychosis patients. Schizophr. Bull. 40, 973–983 (2014).
pubmed: 24687046 pmcid: 4133680 doi: 10.1093/schbul/sbu053
Fraguas, D. et al. Oxidative stress and inflammation in first-episode psychosis: A systematic review and meta-analysis. Schizophr. Bull. 45, 742–751 (2018).
doi: 10.1093/schbul/sby125 pmcid: 6581144
Khoury, R. & Nasrallah, H. A. Inflammatory biomarkers in individuals at clinical high risk for psychosis (CHR-P): State or trait? Schizophr. Res. 199, 31–38 (2018).
pubmed: 29703661 doi: 10.1016/j.schres.2018.04.017
Ferguson, A. T. et al. High frequency of hypermethylation at the 14-3-3 σ locus leads to gene silencing in breast cancer. Proc. Natl. Acad. Sci. 97, 6049–6054 (2000).
pubmed: 10811911 doi: 10.1073/pnas.100566997
Jasinski-Bergner, S. et al. Identification of 14-3-3β Gene as a Novel miR-152 Target Using a Proteome-based Approach. J. Biol. Chem. 289, 31121–31135 (2014).
pubmed: 25228695 pmcid: 4223316 doi: 10.1074/jbc.M114.556290
Leivonen, S.-K. et al. Identification of miR-193b targets in breast cancer cells and systems biological analysis of their functional impact. Mol. Cell. Proteomics MCP 10, M110.005322 (2011).
pubmed: 21512034 doi: 10.1074/mcp.M110.005322
Lin, M. et al. Copy number gain and oncogenic activity of YWHAZ/14-3-3ζ in head and neck squamous cell carcinoma. Int. J. Cancer J. Int. Cancer 125, 603–611 (2009).
doi: 10.1002/ijc.24346
Mhawech, P. et al. Downregulation of 14-3-3σ in ovary, prostate and endometrial carcinomas is associated with CpG island methylation. Mod. Pathol. 18, 340–348 (2005).
pubmed: 15257317 doi: 10.1038/modpathol.3800240
Yu, D. et al. miR-451 protects against erythroid oxidant stress by repressing 14-3-3zeta. Genes Dev. 24, 1620–1633 (2010).
pubmed: 20679398 pmcid: 2912560 doi: 10.1101/gad.1942110
Middleton, F. A., Peng, L., Lewis, D. A., Levitt, P. & Mirnics, K. Altered expression of 14-3-3 genes in the prefrontal cortex of subjects with schizophrenia. Neuropsychopharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol. 30, 974–983 (2005).
doi: 10.1038/sj.npp.1300674
Tylee, D. S., Kawaguchi, D. M. & Glatt, S. J. On the outside, looking in: a review and evaluation of the comparability of blood and brain ‘-omes’. Am. J. Med. Genet. Part B Neuropsychiatr. Genet. Off. Publ. Int. Soc. Psychiatr. Genet. 162B, 595–603 (2013).
doi: 10.1002/ajmg.b.32150
Shimada, T., Fournier, A. E. & Yamagata, K. Neuroprotective function of 14-3-3 proteins in neurodegeneration. BioMed Res. Int. 2013, 564534 (2013).
pubmed: 24364034 pmcid: 3865737 doi: 10.1155/2013/564534
Malaspina, A., Kaushik, N. & de Belleroche, J. A 14-3-3 mRNA is up-regulated in amyotrophic lateral sclerosis spinal cord. J. Neurochem. 75, 2511–2520 (2000).
pubmed: 11080204 doi: 10.1046/j.1471-4159.2000.0752511.x
Kaplan, A., Ottmann, C. & Fournier, A. E. 14-3-3 adaptor protein-protein interactions as therapeutic targets for CNS diseases. Pharmacol. Res. 125, 114–121 (2017).
pubmed: 28918174 doi: 10.1016/j.phrs.2017.09.007
Zhao, J., Meyerkord, C. L., Du, Y., Khuri, F. R. & Fu, H. 14-3-3 proteins as potential therapeutic targets. Semin. Cell Dev. Biol. 22, 705–712 (2011).
pubmed: 21983031 pmcid: 3207012 doi: 10.1016/j.semcdb.2011.09.012
Oppetit, A. et al. The C’JAAD: a French team for early intervention in psychosis in Paris. Early Interv. Psychiatry, https://doi.org/10.1111/eip.12376 (2016).
Yung, A. R. et al. Mapping the onset of psychosis: the Comprehensive Assessment of At-Risk Mental States. Aust. N. Z. J. Psychiatry 39, 964–971 (2005).
pubmed: 16343296 doi: 10.1080/j.1440-1614.2005.01714.x
Krebs, M.-O. et al. [Assessment of mental states at risk of psychotic transition: validation of the French version of the CAARMS]. L’Encéphale 40, 447–456 (2014).
pubmed: 25127895 doi: 10.1016/j.encep.2013.12.003
Morrison, A. P. et al. Early detection and intervention evaluation for people at risk of psychosis: multisite randomised controlled trial. BMJ 344, e2233 (2012).
pubmed: 22491790 pmcid: 3320714 doi: 10.1136/bmj.e2233
Schmittgen, T. D. & Livak, K. J. Analyzing real-time PCR data by the comparative C(T) method. Nat. Protoc. 3, 1101–1108 (2008).
pubmed: 18546601 pmcid: 18546601 doi: 10.1038/nprot.2008.73
Wickham, H. ggplot2: elegant graphics for data analysis. (Springer, 2016).
Harrell, F. E. Jr. & Harrell, M. F. E. Jr. Package ‘Hmisc’. R Found. Stat. Comput. (2018).
Wei, T. et al. Package ‘corrplot’. Statistician 56, 316–324 (2017).
Wie, T. & Simko, V. R package “corrplot”: Visualization of a Correlation Matrix (Version 0.84). Available from https://github.com/taiyun/corrplot (2017)
Harrell, F. E. Jr. et al. Hmisc: Harrell Miscellaneous. R package version 4.4-0. https://CRAN.R-project.org/package=Hmisc (2020).
Lê, S., Josse, J. & Husson, F. FactoMineR: an R package for multivariate analysis. J. Stat. Softw. 25, 1–18 (2008).
doi: 10.18637/jss.v025.i01

Auteurs

Fanny Demars (F)

Université de Paris, Institut of Psychiatry and Neuroscience of Paris (IPNP), INSERM U1266, team Physiopathologie des Maladies Psychiatriques, GDR3557-Institut de Psychiatrie, Paris, France.

Oussama Kebir (O)

Université de Paris, Institut of Psychiatry and Neuroscience of Paris (IPNP), INSERM U1266, team Physiopathologie des Maladies Psychiatriques, GDR3557-Institut de Psychiatrie, Paris, France.
GHU Paris Psychiatrie et Neurosciences, Paris, France.

Aude Marzo (A)

Université de Paris, Institut of Psychiatry and Neuroscience of Paris (IPNP), INSERM U1266, team Physiopathologie des Maladies Psychiatriques, GDR3557-Institut de Psychiatrie, Paris, France.

Anton Iftimovici (A)

Université de Paris, Institut of Psychiatry and Neuroscience of Paris (IPNP), INSERM U1266, team Physiopathologie des Maladies Psychiatriques, GDR3557-Institut de Psychiatrie, Paris, France.
NeuroSpin, Commissariat à l'Energie Atomique, Gif-sur-Yvette, France.

Catherine Schramm (C)

University of Montreal, Sainte Justine Hospital Research Center, Montreal, Canada.

Marie-Odile Krebs (MO)

Université de Paris, Institut of Psychiatry and Neuroscience of Paris (IPNP), INSERM U1266, team Physiopathologie des Maladies Psychiatriques, GDR3557-Institut de Psychiatrie, Paris, France. mo.krebs@ghu-paris.fr.
GHU Paris Psychiatrie et Neurosciences, Paris, France. mo.krebs@ghu-paris.fr.

Boris Chaumette (B)

Université de Paris, Institut of Psychiatry and Neuroscience of Paris (IPNP), INSERM U1266, team Physiopathologie des Maladies Psychiatriques, GDR3557-Institut de Psychiatrie, Paris, France.
GHU Paris Psychiatrie et Neurosciences, Paris, France.
Department of Psychiatry, McGill University, Montreal, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH